Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China’s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A
Gritgen Therapeutics Co., Ltd. (Gritgen), a biotechnology company focused on identifying and developing innovative gene therapy products to achieve "Great Science for Human Health", announced that it has successfully completed enrollment of all 12 patients in the Investigator Initiated Trial (IIT) by May 17, 2023 for GS1191, an innovated gene therapy product for Hemophilia A (HA) treatment. GS1191, is now the first one completing patient enrollment for IIT study in China. Gritgen also announced that the first patient has been dosed in the China Phase I trial (Protocol No.: GS1191-0445-GTHA-CN01) evaluating GS1191 in patients with severe Hemophilia A.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231105390422/en/
Gritgen Therapeutics Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A. (Photo: Business Wire)
The IIT is a single-arm, open-label, single-dose administration clinical trial to evaluate the safety and tolerability of GS1191 in HA patients older than 18 years of age whose endogenous factor VIII (FVIII) activity was lower than 1 IU/dL (<1%). 12 patients with HA were enrolled in two dose groups (6 in the 2E12 vg/kg group and 6 in the 4E12 vg/kg group, respectively). The last patient was enrolled on May 17, 2023, and all the enrolled patients have been followed up for at least 12 weeks after dosing by Aug. 9, 2023. Preliminary results indicate that GS1191 can continuously and significantly improve the endogenous FVIII activity. All the enrolled patients have experienced significant reductions in Annualized Bleeding Rate (ABR) after receiving GS1191 infusions. Currently, all patients enrolled in 4E12 vg/kg dose group have normal FVIII activities with no episodes of bleeding events observed after dosing. Most of the adverse events (AEs) reported in this IIT study were grade 1 in severity. No AEs have been observed in any patients receiving either dose considered to be grade 3 or higher in severity, indicating a favorable safety profile.
GS1191 received clinical trial approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) in January of this year. The IND approval was granted by NMPA in January 2023. This multicenter, single-arm, open-label, single-dose administration Phase 1 study was designed to evaluate the safety, preliminary efficacy, and vector kinetics profile of a single intravenous infusion of GS1191 at different dose levels in patients with severe HA and determine the dose for Phase 2/3 clinical studies based on the patients’ benefit/risk profile. The first patient has been dosed in the China Phase 1 trial on Aug. 2, 2023.
Dr. Wu Fenglan, Co-founder and CEO of Gritgen, commented that, "as the first flagship gene therapy product developed independently by our company, Gritgen's GS1191 has successfully achieved First Patient In Phase I and all the enrollment in the IIT study. We appreciate the investigators, patients and their families as well as our own team, for bringing effective and valuable treatment to HA patients."
GS1191 is the first gene therapy product for HA gaining IND approval in China. Dr. Wu Fenglan further remarked that, "the outstanding safety and efficacy data from IIT have instilled immense confidence in the entire team. Gritgen is committed to developing innovative gene therapy products, revolutionizing the quality of life of patients at the genetic level, and reshaping the clinical treatment pattern of hemophilia A."
About Hemophilia
Hemophilia is an X-linked recessive hereditary bleeding disorder. Epidemiology estimates approximately 120,000 patients with hemophilia in China. This disorder can be classified into Hemophilia A (HA) and Hemophilia B (HB). HA accounts for about 85% of all hemophilia patients, making it the most prevalent subtype. HA results from mutations in the gene encoding FVIII, causing a genetic deficiency of coagulation factor VIII. HB, constitutes about 15% of all hemophilia cases and is caused by mutations in the F9 gene, resulting in an genetic deficiency of coagulation Factor IX. Factor VIII is larger than factor IX, making it the more difficult to be delivered by gene therapy. The success of delivering Factor VIII means that technically, the same team should be able to deliver Factor IX.
The primary manifestations of hemophilia are spontaneous bleeding or excessive bleeding following minor injuries. The standard clinical treatment for hemophilia involves replacement therapy with coagulation factors, requiring lifelong injection of proteins on a regular basis, which brings a significant economic burden to patients, their families, and societies. Gene therapy stands as a cutting-edge technology with the potential to offer a cure for hemophilia patients with a single injection.
About GS1191-0445 Injection
GS1191 is an investigational adeno-associated virus (AAV) gene therapy for the treatment of Hemophilia A. GS1191 can deliver human FVIII gene to patients with Hemophilia A in vivo and achieve long-term gene expression via a single dose of intravenous infusion, thereby raising and sustaining endogenous FVIII activity over the long term. As an innovative treatment, the goal is to achieve a therapeutic effect of "single-dose, long-term efficacy" by addressing the underlying cause and preventing bleeding events.
GS1191 is the first gene therapy product receiving IND approval from NMPA in January 2023, and the first product completing patient enrollment for IIT in China.
About Gritgen
Founded in 2019 by Dr. Yi Rao, a leader of biomedical research in China, Gritgen is dedicated to apply “Great Science for Human Health”. The company has independently developed a globally leading highly efficient GritPAC and GritOcul platform. Combining fundamental understanding of genetics and biology of diseases with modern technologies in molecular biology, Gritgen has developed multiple product pipelines in rare and common diseases to fulfill the unmet medical needs of patients and improve the health of people in China and the world.
Recent News: Gritgen Therapeutics Launches Commercial GMP Facility in Suzhou, China
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231105390422/en/
Contact information
Jiaojiao Xu
PR Manager
Tel: 86+15738823028
E-mail: jiaojiao.xu@gritgen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Hackett Group ® and Celonis Partner to Accelerate ROI With Unmatched AI + Process Intelligence Solutions6.8.2025 00:18:00 EEST | Press release
The Hackett Group, Inc. (NASDAQ: HCKT), a leading generative artificial intelligence (Gen AI) consultancy and executive advisory firm, today announced a collaboration with Celonis, a global leader in process mining, to deliver intelligent enterprise automation that drives measurable business results at unprecedented speed. Using Celonis process intelligence and The Hackett Group’s AI XPLR™ and ZBrain™ platforms – that leverage The Hackett Group’s globally recognized enterprise benchmarking and business transformation IP – companies can compare their performance against Digital World Class® performance standards. This will allow clients to quickly identify the greatest ROI opportunities and harness unmatched process intelligence and agentic workflow solutions to achieve their value realization objectives. The partnership delivers: Clarity on the right tech investments: Combining The Hackett Group’s industry benchmarks with Celonis process intelligence and its own benchmarks on leading m
IFF Reports Second Quarter 2025 Results5.8.2025 23:26:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the second quarter ended June 30, 2025. Management Commentary “IFF’s second-quarter results reflect the progress we are making to strengthen our business and advance our strategic agenda,” said Erik Fyrwald, CEO of IFF. “Our teams delivered top-line growth and improved profitability, driven by disciplined execution and a strong focus on productivity. We also made strides in reshaping our portfolio by closing the divestitures of Pharma Solutions and Nitrocellulose, and successfully completing our debt tender offering - reducing leverage to 2.5x, ahead of our target and reinforcing our financial position.” “Additionally, we announced the expected divestiture of our soy crush, concentrates, and lecithin business - furthering the evolution of our Food Ingredients portfolio toward more value-added offerings. This move aligns with our margin enhancement strategy and supports our continued evaluation of strategic alternatives for this business.”
Cooler Master’s MasterHUB Wins Red Dot Award for Design Excellence5.8.2025 22:36:00 EEST | Press release
Cooler Master, a global leader in innovative thermal solutions and PC hardware, today announced that MasterHUB has won the Red Dot Award in the 2025 Brands & Communication Design category. The Red Dot is an internationally recognized symbol of outstanding design quality, awarded by a jury of global design experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805404259/en/ Cooler Master's Award-Winning MasterHUB Stream Deck. This recognition highlights Cooler Master’s FreeForm 2.0 design philosophy, which empowers users to build personalized, modular systems that evolve with their needs. MasterHUB embodies this approach by offering a flexible foundation for streamers, editors, and creatives to shape their own workflows. “MasterHUB was designed to grow with you,” said Matteo Stracciari, General Manager at Cooler Master. “Whether you're mixing audio, editing video, or live streaming, the modular system adapts to your tools
Yamaha Motor: Consolidated Business Results Summary - First Half of Fiscal Year Ending December 31, 2025 -5.8.2025 20:00:00 EEST | Press release
Yamaha Motor Co., Ltd. (Tokyo: 7272) announces its consolidated business results for the first half of fiscal 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805154633/en/ Yamaha Motor Co., Ltd. Revenues for the period were 1,277.8 billion yen (a decrease of 70.6 billion yen or 5.2% compared with the same period of the previous fiscal year), operating income was 84.1 billion yen (a decrease of 70.0 billion yen or 45.4%), and net income attributable to owners of parent was 53.1 billion (a decrease of 59.8 billion yen or 52.9%). For the first half-year consolidated accounting period, the U.S. dollar traded at 148 yen (an increase of 4 yen from the same period of the previous fiscal year) and the euro at 162 yen (an increase of 3 yen). Declining unit sales in motorcycles, personal watercraft, and golf cars led to lower revenues. For operating income, the decrease in unit sales and higher R&D expenses in the core motorcy
Textron Aviation Announces Additional Garmin Avionics Upgrade Option for Cessna Citation CJ15.8.2025 19:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced customers can now upgrade their Cessna Citation CJ1 with the all-Garmin retrofit solution following Federal Aviation Administration (FAA) supplemental type certification (STC). Customers can have the upgrade installed at any of the company’s global service network locations to add significant technological advances and new capabilities to their aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805392790/en/ Textron Aviation announced customers can now upgrade their Cessna Citation CJ1 with the all-Garmin retrofit solution following Federal Aviation Administration (FAA) supplemental type certification (STC). The Garmin avionics upgrade — including the new, larger 12-inch G600 TXi flight display, TXi EIS, GTN™ 750Xi GPS/NAV/COMM and GFC™ 600 digital autopilot — is a cutting-edge solution for the CJ1 cockpit. The system offers situational aware
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom